Protein / target

Sodium/potassium-transporting ATPase subunit beta-2

ATP1B2P14415Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
5
Approved medicines
30
Clinical trials
Small-molecule tractable
Druggability
Advanced Clinical

Protein at a glance

Biological role

Protein-macromolecule adaptor activity

Primary system

Nervous system

Strongest disease association

type 2 diabetes mellitus

Genetic evidence · score 0.67

Therapeutic maturity

Clinically validated target

5 approved medicines against this target

Druggability

Small molecule

Open Targets tractability · Advanced Clinical

Clinical development

5 approved · 1 in clinical development

30 linked trials

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function

This is the non-catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane. The exact function of the beta-2 subunit is not known

Subcellular location

Cell membrane
Domains and Gene Ontology detail (38)

Gene Ontology

  • Capical plasma membrane
  • Castrocyte end-foot
  • Castrocyte projection
  • Ccell body membrane
  • Ccell periphery
  • Ccell projection membrane
  • Ccytoplasm
  • Cexternal side of plasma membrane
  • Clateral plasma membrane
  • Cmembrane
  • Cneuron to neuron synapse
  • Cphotoreceptor inner segment

290 aa · 33 kDa

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Synaptic signallingGO
View supporting evidence

Synaptic signalling

  • ·neuron to neuron synapse
View underlying pathways (4)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

ATP1A2ATP1A3ATP1A1ATP1A4ATP1B1FXYD2ATP1B3FXYD1PRKG1ATP1B4ATP1B2

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Drugs targeting this protein

1

Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.

Digoxin
ApprovedInhibitor

Sodium/potassium-transporting ATPase inhibitor

Appears in clinical studies involving congestive heart failure, atrial fibrillation, heart failure, cardiovascular disorder

Acts on a complex — shared with ATP1A1, ATP1B1, ATP1A2 +4 more · 1 of 8 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.

Translational evidence

Open Targets 26

Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.

Strongest genetic associations

Human genetic evidence — the most direct causal link between this target and a disease.

type 2 diabetes mellitus0.67

Genetic · overall 0.43

testicular disorder0.39

Genetic · overall 0.24

atrial fibrillation0.29

Genetic · overall 0.64

Highest-confidence therapeutic associations

Diseases where a drug acting on this target has already reached clinical development.

congestive heart failure0.99

Clinical · overall 0.60

heart failure0.95

Clinical · overall 0.58

cardiovascular disorder0.91

Clinical · overall 0.55

Arrhythmia0.83

Clinical · overall 0.50

Supraventricular tachycardia0.53

Clinical · overall 0.32

Highest overall evidence

Remaining associations by Open Targets' aggregated evidence score.

atrial flutter0.26

Clinical

neurodegenerative disease0.25

Pathway

Show all associations
atrial fibrillation0.64
congestive heart failure0.60
heart failure0.58
cardiovascular disorder0.55
Arrhythmia0.50
type 2 diabetes mellitus0.43
Supraventricular tachycardia0.32
atrial flutter0.26
neurodegenerative disease0.25
testicular disorder0.24

Open Targets ranks 3,271 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.

Known drugs · 6 total

DIGOXINApproval

congestive heart failure · atrial fibrillation · heart failure

DIGITOXINApproval

cardiovascular disorder · Arrhythmia · heart failure

LANATOSIDE CApproval

cardiovascular disorder

DESLANOSIDEApproval

cardiovascular disorder · Arrhythmia · heart failure

ISTAROXIMEPhase 2 3

heart disorder · heart failure · heart failure

ACETYLDIGITOXINApproval

cardiovascular disorder · congestive heart failure

Tractability

SM · Advanced ClinicalSM · High-Quality LigandSM · Druggable FamilyAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMMPR · Database UbiquitinationPR · Half-life Data

Safety liabilities

atrioventricular blockdecreased heart rateincreased urine excretionvomitingincreased cardiac contractilitycardiac arrhythmiaincreased urinary sodium excretionventricular fibrillation

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.

Show remaining trials (24)

RECRUITING · via Digoxin · NCT06588699

ClinicalTrials.gov via the drug-target graph.

Forefront confidence

Synthesis

Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.

atrial fibrillationWell supported
0.81
agreement 0.710.91
Clinical72%Genetic28%

Open Targets aggregate 0.64 · 2 independent evidence families

congestive heart failureModerately supported
0.74
agreement 0.570.91
Clinical100%

Open Targets aggregate 0.60 · 1 independent evidence family

heart failureModerately supported
0.71
agreement 0.550.88
Clinical100%

Open Targets aggregate 0.58 · 1 independent evidence family

type 2 diabetes mellitusModerately supported
0.70
agreement 0.600.80
Genetic88%Clinical12%

Open Targets aggregate 0.43 · 2 independent evidence families

cardiovascular disorderModerately supported
0.68
agreement 0.520.84
Clinical100%

Open Targets aggregate 0.55 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.

What's happening now

3

Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.

  1. Trial status changed2026-07-20

    A Phase 1 Study to Evaluate the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of Cocktail Probe Substrates of CYP3A and Select Transporters in Healthy Adult Subjects

    Status changed to Active, not recruiting · ClinicalTrials.gov · via Digoxin

  2. New publication2024-01-25
    Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review.

    Drug safety · 2024 · 37 citations · Europe PMC · via Digoxin

  3. New publication2002-12-01
    Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.

    JAMA · 2002 · 1,354 citations · Europe PMC · via Digoxin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.